These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21439443)

  • 61. Can we quantify the benefits of DMDs in multiple sclerosis?
    Thompson A
    Lancet Neurol; 2006 Apr; 5(4):290-1. PubMed ID: 16545743
    [No Abstract]   [Full Text] [Related]  

  • 62. Pediatric multiple sclerosis: Escalation and emerging treatments.
    Chitnis T; Ghezzi A; Bajer-Kornek B; Boyko A; Giovannoni G; Pohl D
    Neurology; 2016 Aug; 87(9 Suppl 2):S103-9. PubMed ID: 27572854
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.
    Amato MP; Portaccio E
    CNS Drugs; 2015 Mar; 29(3):207-20. PubMed ID: 25773609
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunomodulatory therapies delay disease progression in multiple sclerosis.
    Bergamaschi R; Quaglini S; Tavazzi E; Amato MP; Paolicelli D; Zipoli V; Romani A; Tortorella C; Portaccio E; D'Onghia M; Garberi F; Bargiggia V; Trojano M
    Mult Scler; 2016 Nov; 22(13):1732-1740. PubMed ID: 22653657
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Switching therapies in MS: what are the options?
    Markowitz CE
    J Clin Psychiatry; 2015 Feb; 76(2):e6. PubMed ID: 25742221
    [No Abstract]   [Full Text] [Related]  

  • 66. Rationale for early intervention with immunomodulatory treatments.
    Tintoré M
    J Neurol; 2008 Mar; 255 Suppl 1():37-43. PubMed ID: 18317675
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Multiple sclerosis at the time of world-wide use of disease modifying treatment].
    Gusev EI; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):4-9. PubMed ID: 19894306
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Therapies in multiple sclerosis].
    Kesselring J
    Praxis (Bern 1994); 2013 Aug; 102(17):1061-7. PubMed ID: 23965719
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Relapses in multiple sclerosis: Relationship to disability.
    Goodin DS; Reder AT; Bermel RA; Cutter GR; Fox RJ; John GR; Lublin FD; Lucchinetti CF; Miller AE; Pelletier D; Racke MK; Trapp BD; Vartanian T; Waubant E
    Mult Scler Relat Disord; 2016 Mar; 6():10-20. PubMed ID: 27063617
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.
    Wiendl H; Meuth SG
    Drugs; 2015 Jun; 75(9):947-77. PubMed ID: 26033077
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Assessing risks of multiple sclerosis therapies.
    Parfenov V; Schluep M; Du Pasquier R
    J Neurol Sci; 2013 Sep; 332(1-2):59-65. PubMed ID: 23835089
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapies for multiple sclerosis: translational achievements and outstanding needs.
    Haghikia A; Hohlfeld R; Gold R; Fugger L
    Trends Mol Med; 2013 May; 19(5):309-19. PubMed ID: 23582699
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis.
    Claflin SB; Tan B; Taylor BV
    Mult Scler Relat Disord; 2019 Nov; 36():101374. PubMed ID: 31450158
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Infection risk in patients on multiple sclerosis therapeutics.
    Williamson EM; Berger JR
    CNS Drugs; 2015 Mar; 29(3):229-44. PubMed ID: 25761739
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk stratification and mitigation multiple sclerosis.
    Ontaneda D; Cohn S; Fox R
    Mult Scler Relat Disord; 2014 Sep; 3(5):639-49. PubMed ID: 25221744
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command.
    Freedman MS; Cohen B; Dhib-Jalbut S; Jeffery D; Reder AT; Sandberg-Wollheim M; Weinstock-Guttman B
    Curr Med Res Opin; 2009 Oct; 25(10):2459-70. PubMed ID: 19678753
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
    Feinstein A; Freeman J; Lo AC
    Lancet Neurol; 2015 Feb; 14(2):194-207. PubMed ID: 25772898
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Disability Progression in SPMS Despite Therapeutic Intervention: Refractory SPMS].
    Ochi H
    Brain Nerve; 2022 May; 74(5):496-504. PubMed ID: 35589638
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
    Kieseier BC; Stüve O
    Nat Rev Neurol; 2011 May; 7(5):255-62. PubMed ID: 21467994
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Natural history of multiple sclerosis].
    Vukusic S; Confavreux C
    Presse Med; 2010 Mar; 39(3):359-62. PubMed ID: 20089380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.